Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom. Show more

14/15 Conduit Street, London, W1S 2XJ, United Kingdom

https://www.tizianalifesciences.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

175.6M

52 Wk Range

$1.14 - $2.60

Previous Close

$1.38

Open

$1.40

Volume

274,680

Day Range

$1.38 - $1.67

Enterprise Value

172.1M

Cash

4.01M

Avg Qtr Burn

N/A

Insider Ownership

43.48%

Institutional Own.

2.94%

Qtr Updated

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Intranasal Foralumab Details Alzheimer's disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Foralumab Details COVID-19	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milciclib (pan-CDK inhibitor) Details Hepatocellular carcinoma, Solid tumor/s	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intranasal Foralumab (anti-CD3 mAb) Details Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS)	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intranasal Foralumab (anti-CD3 mAb) Details Multiple System Atrophy	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Foralumab (anti-CD3 mAb) Details Crohns disease	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intranasal Foralumab (anti-CD3 mAb) Details Neurodegenerative disease, Amyotrophic lateral sclerosis	IND Acceptance decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.